Department of Pathology, The University of Melbourne, Australia.
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2833-40. doi: 10.1098/rstb.2011.0093.
Increased international support for both research into new vaccines and their deployment in developing countries has been evident over the past decade. In particular, the GAVI Alliance has had a major impact in increasing uptake of the six common infant vaccines as well as those against hepatitis B and yellow fever. It further aims to introduce pneumococcal and rotavirus vaccines in the near future and several others, including those against human papillomavirus, meningococcal disease, rubella and typhoid not long after that. In addition, there is advanced research into vaccines against malaria, HIV/AIDS and tuberculosis. By 2030, we may have about 20 vaccines that need to be used in the developing world. Finding the requisite funds to achieve this will pose a major problem. A second and urgent question is how to complete the job of global polio eradication. The new strategic plan calls for completion by 2013, but both pre-eradication and post-eradication challenges remain. Vaccines will eventually become available beyond the field of infectious diseases. Much interesting work is being done in both autoimmunity and cancer. Cutting across disease groupings, there are issues in methods of delivery and new adjuvant formulations.
在过去十年中,国际社会对新型疫苗的研究及其在发展中国家的应用的支持明显增加。特别是,全球疫苗免疫联盟(GAVI Alliance)在提高六种常见婴儿疫苗以及乙型肝炎和黄热病疫苗的接种率方面发挥了重要作用。它还旨在近期引入肺炎球菌和轮状病毒疫苗,并在不久之后引入其他疫苗,包括针对人乳头瘤病毒、脑膜炎球菌病、风疹和伤寒的疫苗。此外,疟疾、艾滋病毒/艾滋病和结核病疫苗的研究也在深入进行中。到 2030 年,我们可能需要在发展中国家使用约 20 种疫苗。找到实现这一目标所需的资金将是一个重大问题。第二个紧迫的问题是如何完成全球根除脊髓灰质炎的工作。新的战略计划要求在 2013 年完成,但在根除之前和之后仍存在挑战。疫苗最终将在传染病领域之外使用。在自身免疫和癌症方面都在进行着许多有趣的工作。跨越疾病分组,在疫苗接种方法和新型佐剂配方方面存在问题。